LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade

Immune checkpoint blocking antibodies are a cornerstone in cancer treatment; however, they benefit only a subset of patients and biomarkers to guide immune checkpoint blockade (ICB) treatment choices are lacking. We designed this study to identify blood-based correlates of clinical outcome in ICB-tr...

Full description

Bibliographic Details

Published in:	Science translational medicine Vol. 13; no. 608
Main Authors:	Shen, Ronglai, Postow, Michael A, Adamow, Matthew, Arora, Arshi, Hannum, Margaret, Maher, Colleen, Wong, Phillip, Curran, Michael A, Hollmann, Travis J, Jia, Liwei, Al-Ahmadie, Hikmat, Keegan, Niamh, Funt, Samuel A, Iyer, Gopa, Rosenberg, Jonathan E, Bajorin, Dean F, Chapman, Paul B, Shoushtari, Alexander N, Betof, Allison S, Momtaz, Parisa, Merghoub, Taha, Wolchok, Jedd D, Panageas, Katherine S, Callahan, Margaret K
Format:	Journal Article
Language:	English
Published:	United States 25.08.2021
Subjects:	Biomarkers, Tumor Carcinoma, Transitional Cell Humans Immune Checkpoint Inhibitors T-Lymphocytes Urinary Bladder Neoplasms
ISSN:	1946-6242, 1946-6242
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!